文献速递急性肾损伤慢性肾脏病

肾内科随访与常规照护对急性肾损伤住院后患者的影响:FUSION随机对照试验

Nephrologist Follow-Up versus Usual Care after an Acute Kidney Injury Hospitalization (FUSION): A Randomized Controlled Trial.
PubMed 文献 · Clin J Am Soc Nephrol · 2021-05-21

FUSION试验在加拿大四家医院将KDIGO 2-3期AKI住院患者随机分为早期肾内科随访或常规照护,71例患者纳入分析。肾内科随访组71%接受专科访视,常规组仅8%;1年主要不良肾脏事件两组分别为44%与43%,相对风险1.02(95%CI 0.60-1.73)。研究认为面对面随访模式存在多种障碍,许多患者不接受。

要点

  • AKI幸存者1年主要不良肾脏事件(死亡、维持透析或CKD)发生率约40%以上
  • 面对面肾内科随访模式招募困难,仅26%符合条件者被随机
  • 肾内科随访与常规照护相比,1年主要不良肾脏事件无显著差异

核心结论

  • AKI幸存者主要不良肾脏事件常见,但面对面肾内科随访模式存在多种障碍,许多患者不接受。

研究设计与样本

  • 随机对照试验,在加拿大多伦多四家医院纳入KDIGO 2-3期AKI住院患者。
  • 2015年7月至2017年6月筛查3687例,269例符合条件,随机71例(26%),其中肾内科随访组34例、常规照护组37例。

主要发现

  • 肾内科访视在随访组34例中发生24例(71%),常规组37例中发生3例(8%)。
  • 1年主要不良肾脏事件(死亡、维持透析或新发/进展性CKD)在随访组34例中发生15例(44%),常规组37例中发生16例(43%)。
  • 相对风险为1.02(95%CI 0.60-1.73)。
  • 拒绝入组的主要原因包括住院相关疲劳(n=65)、不愿增加医生(n=59)和长途旅行(n=40)。

临床怎么用

  • 面对面肾内科随访模式在AKI幸存者中可行性受限,需探索替代随访方式。
  • AKI幸存者主要不良肾脏事件风险高,应关注血压控制、心血管风险降低和用药安全。

局限性

  • 该研究为2年先锋阶段试验,样本量小(71例),主要目的是评估可行性。
  • 招募率低(26%),可能存在选择偏倚,影响结果外推。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVES: Survivors of AKI are at higher risk of CKD and death, but few patients see a nephrologist after hospital discharge. Our objectives during this 2-year vanguard phase trial were to determine the feasibility of randomizing survivors of AKI to early follow-up with a nephrologist or usual care, and to collect data on care processes and outcomes. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: We performed a randomized controlled trial in patients hospitalized with Kidney Disease Improving Global Outcomes (KDIGO) stage 2-3 AKI at four hospitals in Toronto, Canada. We randomized patients to early nephrologist follow-up (standardized basket of care that emphasized BP control, cardiovascular risk reduction, and medication safety) or usual care from July 2015 to June 2017. Feasibility outcomes included the proportion of eligible patients enrolled, seen by a nephrologist, and followed to 1 year. The primary clinical outcome was a major adverse kidney event at 1 year, defined as death, maintenance dialysis, or incident/progressive CKD. RESULTS: We screened 3687 participants from July 2015 to June 2017, of whom 269 were eligible. We randomized 71 (26%) patients (34 to nephrology follow-up and 37 to usual care). The primary reason stated for declining enrollment included hospitalization-related fatigue (n=65), reluctance to add more doctors to the health care team (n=59), and long travel times (n=40). Nephrologist visits occurred in 24 of 34 (71%) intervention participants, compared with three of 37 (8%) participants randomized to usual care. The primary clinical outcome occurred in 15 of 34 (44%) patients in the nephrologist follow-up arm, and 16 of 37 (43%) patients in the usual care arm (relative risk, 1.02; 95% confidence interval, 0.60 to 1.73). CONCLUSIONS: Major adverse kidney events are common in AKI survivors, but we found the in-person model of follow-up posed a variety of barriers that was not acceptable to many patients. CLINICAL TRIAL REGISTRY NAME AND REGISTRATION NUMBER: Nephrologist Follow-up versus Usual Care after an Acute Kidney Injury Hospitalization (FUSION), NCT02483039 CJASN 16: 1005-1014, 2021. doi: https://doi.org/10.2215/CJN.17331120.

来源:Clin J Am Soc Nephrol,查看原文。版权归原作者所有。

引用

  1. Silver SA, Adhikari NK, Bell CM, et al. Nephrologist Follow-Up versus Usual Care after an Acute Kidney Injury Hospitalization (FUSION): A Randomized Controlled Trial. Clin J Am Soc Nephrol. 2021. PMID: 34021031. doi:10.2215/CJN.17331120

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。